Acrotech Biopharma LLC

ARKAY Therapeutics is a pioneering pharmaceutical company based in Hightstown, NJ, at the forefront of modern innovative medicine. Their mission is to change the current trajectory of Type 2 diabetes by developing groundbreaking therapies that address the failures of existing treatments and improve patient outcomes. With a patient-centric approach, ARKAY focuses on preserving beta cell function, decreasing insulin resistance, and providing sustained glycemic control. Their flagship product, TriGlytza, targets the multidimensional pathophysiology of Type 2 diabetes and aims to restore beta cell function, prevent beta cell failure, and maintain insulin sufficiency. ARKAY Therapeutics stands out in the diabetes space by offering a unique and comprehensive solution to the complex metabolic disorder. Unlike traditional drugs that treat Type 2 diabetes in isolation, TriGlytza considers comorbidities and coexisting conditions, providing a holistic approach to treatment. Backed by scientific rationale and supported by clinical studies, TriGlytza has the potential to revolutionize the management of Type 2 diabetes and improve the lives of millions of patients worldwide.Generated from the website

Par Pharmaceuticals Inc, based in Cranbury, NJ, is a highly focused generic pharmaceutical company that has been providing patients and customers with uncompromising quality and value for over 40 years. They are dedicated to delivering high-quality, cost-effective medicines through excellence in innovation, development, manufacturing, and commercialization, specializing in modified-released oral solid dosage forms and non-oral dosage forms. Par Sterile Products, a division of Par Pharmaceuticals, develops, manufactures, and markets a broad portfolio of branded and generic aseptic injectable products. With a sterile manufacturing facility located in Rochester, Michigan, they have gained an unparalleled reputation for high-quality products and regulatory compliance.Generated from the website

Novo Nordisk Pharmaceuticals, located in Plainsboro, NJ, specializes in innovative treatments for various disease areas, with a strong focus on diabetes and obesity management. The company is committed to sustainable business practices and actively engages in partnerships to drive innovation in healthcare. In recent developments, Novo Nordisk reported a significant increase in sales and is advancing its product offerings, including the potential first oral GLP-1 treatment for obesity. The company emphasizes transparency in employee health coverage and encourages prospective candidates to explore career opportunities within the organization. Generated from the website